Src inhibitors Dasatinib and Bosutinib, reported to cross the blood-brain barrier (Porkka et al., 2008; Liang et al., 2009), have been approved for therapeutic use in humans (Hochhaus and Kantarjian, 2013; Hill et al., 2014) for the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.